Cutaneous Polyarteritis Nodosa in Childhood: A Case Report and Review of the Literature by Bansal, Nina-Karen & Houghton, Kristin Michelle
Hindawi Publishing Corporation
Arthritis
Volume 2010, Article ID 687547, 7 pages
doi:10.1155/2010/687547
Clinical Study
CutaneousPolyarteritis NodosainChildhood:
A Case Report and Review of the Literature
Nina-KarenBansaland KristinMichelle Houghton
Division of Rheumatology, British Columbia Children’s Hospital, K4-123 ACB, 4480 Oak Street, Vancouver, BC, Canada V6H 3V4
Correspondence should be addressed to Kristin Michelle Houghton, khoughton@cw.bc.ca
Received 11 August 2010; Revised 4 October 2010; Accepted 28 October 2010
Academic Editor: Lucy R. Wedderburn
Copyright © 2010 N.-K. Bansal and K. M. Houghton. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Polyarteritis nodosa is a rare vasculitis of childhood. Cutaneous PAN (cPAN) is limited to the skin, muscles, joints, and peripheral
nerves. We describe a 7.5-year-old girl with cPAN presenting initially as massive cervical edema who later went on to develop
subcutaneous nodules, livedo reticularis, myositis, arthritis, and mononeuritis multiplex. The use of corticosteroids resulted in
initial clinical improvement, but symptom recurrence necessitated disease modifying antirheumatic drugs and biologic therapy.
Wereviewafurther119reportsofbiopsyprovencPANintheliterature.Amajorityofpatients(96.6%)hadcutaneousinvolvement;
musculoskeletal involvement was common and included both articular (58.0%) and muscular (42.9%) symptoms, and nervous
system involvement was least common (18.5%). Corticosteroids were used in the majority of patients (85.7%), followed
by use of disease modifying antirheumatic drugs (33.0%), nonsteroidal anti-inﬂammatory drugs (10.7%), and intravenous
immunoglobulin (9.8%). Therapy of cPAN with biologics has only been reported in 2 patients, and we report the ﬁrst patient
treated with Rituximab. A diagnosis of cPAN should be considered in a child with fever, vasculitic rash, and musculoskeletal
symptoms. Most children respond to corticosteroids and have a benign course, but some require disease modifying antirheumatic
drugs and biologic therapies.
1.Introduction
Polyarteritis nodosa (PAN) is a rare vasculitis in childhood.
Since ﬁrst described by Kussmaul and Maier in 1866 [1],
there have been approximately 200 pediatric case reports
in the literature. Traditionally, children were classiﬁed as
havingoneofthreeforms:infantile,cutaneous,andsystemic.
Infantile PAN is now recognized asa severeformof Kawasaki
disease.CriteriaforadiagnosisofsystemicPANinchildhood
have been proposed but not validated [2].
Cutaneous PAN (cPAN) is recognized as a separate
entity but there are no diagnostic criteria for cPAN. [2]
cPAN is characterized by disease aﬀecting the skin with no
major organ system involvement. The cutaneous symptoms
are similar to systemic PAN and mild fever, muscle, joint,
and peripheral nervous system involvement may also occur.
Fever, rash, and musculoskeletal symptoms are common in
children and cPAN needs to be diﬀerentiated from other
diagnostic entities. Deﬁnitive diagnosis is by histopathologic
evidence of necrotizing inﬂammation of the medium and
small-sized arteries. There is a paucity of knowledge of
the spectrum of clinical presentation and management of
children with cPAN. We describe a severe case of cPAN and
summarize the clinical manifestations, laboratory data and
treatment regimens of our patient as well as those reported
intheliterature.Toourknowledge,wereporttheﬁrstpatient
with childhood cPAN treated with Rituximab, and we report
the largest pediatric review of cPAN.
2.MaterialsandMethods
This is a case study and review of the literature of childhood
cPANwithanalysisoftheclinicalandlaboratoryfeaturesand
treatment practice.
2.1.LiteratureReview. AllcasereportsandcaseseriesofPAN
inchildhoodreportedintheEnglishLiteraturebetween19502 Arthritis
and 2009 identiﬁed through Medline were reviewed. There is
no strict deﬁnition of cPAN and we included all reports of
childrenaged18andyoungerwithskininvolvement,absence
of visceral involvement, and biopsy evidence of necrotizing
inﬂammation of small and medium-sized arteries.
Exclusion criteria were the presence of another identiﬁed
vasculitis including systemic PAN, infantile PAN, micro-
scopic polyangiitis, and Hepatitis B-associated PAN.
Data collection, by chart review or extraction of infor-
mationfromindividualpublications,includeddemographic,
clinical, laboratory, and treatment information. Few reports
have complete data; therefore, depending on the avail-
ability for each reported variable, the denominator used
for analysis varies. The following clinical and laboratory
measures were recorded: skin, muscle, joint and nervous
system involvement, antistreptolysin O titre (ASOT), throat
swab, and hepatitis B serology. Treatment was classiﬁed into
one of the following groups: corticosteroid, nonsteroidal
anti-inﬂammatory drug (NSAID), acetylsalicylic acid (ASA),
disease modifying antirheumatic drug (DMARD), intra-
venousimmunoglobulin(IVIG),biologictherapy,penicillin,
or other medication.
2.2. Statistical Analysis. Descriptive statistics were calculated
for demographic, clinical, laboratory, and treatment data.
Medians, ranges, and percentages are presented as appropri-
ate.
2.3. Case Report. A 7.5-year-old previously healthy female
of mixed Caucasian-Middle Eastern descent presented to the
emergency department with unilateral mandibular swelling
a n dn e c kp a i no np a s s i v em o v e m e n t .S h eh a db e e np r e -
scribed erythromycin for 3 days of pharyngitis and 1
day of fever. She did not have hoarseness, drooling, or
respiratory distress. There was no recent travel, TB exposure,
or animal contact. Her father had recently been treated
for a streptococcal pharyngitis; otherwise there were no ill
contacts.
Past medical history was unremarkable. She was fully
immunized.
On examination she looked well. She was febrile at
38.2
◦C; the rest of her vital signs were normal. She had soft
tissue swelling along the left mandible extending down the
neck. She had mild left cervical adenopathy that was tender
to palpation. She was unable to fully ﬂex and rotate her
neck due to pain. The remainder of the examination was
unremarkable. Complete blood count revealed leukocytosis
(29.7 × 109/L) with neutrophilia (26.34 × 109/L), normal
hemoglobin (118g/L), and thrombocytosis (466 × 109/L).
CRP and ESR were elevated at 77mg/L and 47mm/hr,
respectively. Electrolytes, renal function, and amylase were
normal. Lateral neck X-ray revealed mild thickening of the
prevertebral soft tissues. She was diagnosed with cervical
adenitis and admitted for antibiotic therapy.
After admission, she clinically deteriorated. She had
daily fevers and the edema increased and spread to the
right mandible and anterior chest wall. On day 5 she
developed a pruritic papular erythematous rash over her
chin, neck, chest, and back. She had palmar erythema and
erythematous papules on the dorsum of both feet. On day
8 she developed arthralgias of the left knee and ankles,
bilateral calf pain, localized bone pain over the diaphysis
of her right tibia, and pain over the dorsum of both feet.
She had bilateral ankle eﬀusions and was unable to weight
bear.
Her clinical course was further complicated by acute
renal failure, presumed to be secondary to combined van-
comycin,andNSAIDnephrotoxicity.Shealsohadanepisode
of hematemesis, mild hepatitis, and coagulopathy.
ESR, CRP, and platelet count were persistently elevated,
indicative of an extensive inﬂammatory process. Bacterial
cultures of blood, throat (Group A Strep), and lymph node
aspirate were negative. Serology for CMV, EBV, HHV-6,
hepatitis A, B and C, and Toxoplasmosis were negative.
AntistreptolysinOtitrewaselevated(643IU/mL),suggesting
a poststreptococcal phenomenon. IgG titre to Bartonella
henselae was elevated at 1:320, of unclear signiﬁcance.
ANCA, ANA, ENA, and dsDNA were all negative. An
echocardiogram showed normal cardiac anatomy and func-
tion. Ultrasound and CT of the neck and chest demonstrated
moderate lymph node enlargement and soft tissue edema,
but no abscess or lymphatic mass. Bronchoscopy revealed
50% pharyngeal narrowing and was complicated by acute
upper airway compromise that improved with oral dex-
amethasone 0.3mg/kg. Ultrasound of her lower extremities
was negative for deep vein thrombosis but demonstrated
left knee eﬀusion. A skin biopsy of a vasculitic lesion from
the anterior chest wall revealed septal panniculitis with
leukocytoclastic vasculitis involving the small- and medium-
sized blood vessels consistent with cPAN. No granulomas or
microorganisms were seen (Figure 1).
Her treatments included prolonged intravenous antibi-
otics with no eﬀect (cefazolin days 1 to 3, cefuroxime and
clindamycindays3to5,vancomycindays5to13,pipercillin-
tazobactam days 5 to 18). IVIg (2g/kg) was given (on day
11) for possible atypical Kawasaki disease without eﬀect. Her
hematemesis and coagulopathy responded to pantoprazole
andvitaminK.Afterreviewoftheskinbiopsyresults,shewas
treated with pulse doses of intravenous methylprednisolone
(30mg/kg/day) (days 13 to 15), then moderate dose oral
prednisone 1mg/kg/day. Her rash, edema, and arthritis
quickly responded to corticosteroids. On day 21 she was
discharged on oral prednisone.
Her fever, rash, and leg pain recurred when prednisone
was tapered. NSAIDs were initially helpful, but she soon
required admission for intravenous analgesia. On examina-
tion she was febrile and hypertensive. She had polyarthritis.
Her neurologic exam revealed spastic catch at both ankles
with diminished strength (4 − 4+/5) in hip ﬂexion and
extension, and knee extension. Gower’s sign was positive.
Cerebellar exam was normal but on gait testing she toe-
walked and was unable to perform tandem gait. Skin
examination revealed palmar and palatal erythema. She had
livedo reticularis and subcutaneous nodules on her arms and
legs.
Nerve conduction studies demonstrated diminished
amplitude of the left peroneal and right median motors;Arthritis 3
(a) (b)
Figure 1:Histopathologyofavasculiticlesionfromtheanteriorchestwallshowsseptalpanniculitiswithleukocytoclasticvasculitisinvolving
asmallarteryconsistentwithcPAN.Nogranulomasormicroorganismswereseen.(FigurecourtesyofOana-EugeniaPopescu,MD,Division
of Anatomical Pathology, Children’s and Women’s Health Centre of BC).
diminished conduction velocity of the tibial motors bilater-
ally; and absent F response in the left peroneal motor. These
ﬁndings were compatible with mononeuritis multiplex. MRI
of the spine and renal angiogram were normal. She was
treated with pulse doses of intravenous methylprednisolone
(30mg/kg), intravenous cyclophosphamide (500mg/m2),
IVIg (2g/kg), naproxen, gabapentin, and amlodipine. Her
symptoms improved, and she was discharged on day 8,
on high dose oral prednisone, monthly cyclophosphamide
infusions (1000g/m2), naproxen and gabapentin.
She was maintained on monthly infusions of cyclophos-
phamide (1g/m2) and methylprednisolone and was able to
slowly wean gabapentin, naproxen, and oral prednisone.
After 8 months, cyclophosphamide infusions were stretched
to every 2 months. However, she had a ﬂare of her disease
that necessitated admission to hospital. After a 10th dose
of cyclophosphamide she was started on subcutaneous
methotrexate 0.5mg/kg weekly and cyclophosphamide was
discontinued to minimize cumulative cyclophosphamide
exposure. After 1 month, because of persistent symptoms,
methotrexate was increased to 0.75mg/kg and monthly
Inﬂiximab (5mg/kg) infusions were started. Inﬂiximab
was increased to 10mg/kg/doseq 4 weeks, and she was
maintainedonmoderatedoseprednisone,methotrexate,and
naproxen. She remained corticosteroid dependent and had a
ﬂare of her arthritis, rash, fever, and mononeuritis multiplex
with weaning of prednisone below 0.5mg/kg/day. After 8
doses of inﬂiximab she remained corticosteroid-dependent
and a decision was made to stop inﬂiximab and start ritux-
imab. Our patient did not have any positive autoantibodies
and rituximab was chosen as it has been reported to be of
beneﬁt in recalcitrant pediatric vasculitides. [3]S h er e c e i v e d
rituximab (375mg/m2) andcyclophosphamide (500mg/m2)
at days 1 and 15. She has done well since receiving rituximab
and has tolerated weaning of prednisone.
3. Results
Review of the literature identiﬁed 582 cases of PAN, includ-
ing 140 cases of cPAN in case reports and small case
series. 463 were excluded: systemic PAN (327), infantile
PAN (37), hepatitis B-associated PAN (24), microscopic
polyangiitis (53), other vasculitis (1), and cPAN with
absence of histopathological conﬁrmation of the diagnosis
or incomplete clinical datasets (21). 119 cases of cPAN met
our inclusion criteria of age 18 and younger with skin
involvement, absence of visceral involvement, and biopsy
evidence of necrotizing inﬂammation of small and medium
sized arteries.
Clinical information for the 119 cases of cPAN is
summarized in Table 1. The female:male ratio was 1.2:1.
The median age was 10 years (range 7 months to 18 years).
As expected, the majority of patients (96.6%) exhibited cuta-
neous symptoms, including subcutaneous nodules, livedo
reticularis, purpura, edema, and/or ulcers. Musculoskeletal
involvement was common with arthralgias and/or arthritis
reported in 58.0% and myalgias and/or myositis in 42.9% of
cases. Nervous system involvement was least common with
18.5% of cases reporting mononeuritis multiplex, peripheral
neuropathy, cranial nerve palsy, and/or abnormal nerve
conduction. All 119 patients had documented skin or muscle
biopsies demonstrating necrotizing vasculitis of the small-
and medium-sized arteries.
Testing for group A streptococcal infection was positive
in 86.2% of cases (50 of 58 tested), as manifested by elevated
ASOT and/or positive throat swab.
Therapy is summarized in Table 2. Corticosteroids were
used in the majority of patients (85.7%). Various DMARDs,
including azathioprine, cyclophosphamide, methotrexate,
and mycophenolate mofetil were used in (33.0%) of patients.
NSAIDs were prescribed in 10.7% of cases, ASA in 10.7%,
and IVIG in 9.8%. Therapy of cPAN with biologics (inﬂix-
imab, etanercept) has only been reported in 2 patients [3].
Other therapies were used in 10.7% of cases and included
colchicine, dapsone, oxpentifylline, ACTH, and platonin.
4. Discussion
cPAN is not common in the pediatric population with
approximately 140 cases reported in the literature. Disease4 Arthritis
Table 1: Frequency of system involvement in childhood cPAN (N = 119).
Study Total (N)
Skin involvement
(Subcutaneous
nodules, livido
reticularis, purpura,
edema, and/or
ulcers)
Joint involvement
(Arthralgia,
arthritis)
Muscle involvement
(Myalgias, myositis)
Nerve involvement
(Mononeuritis
multiplex, peripheral
neuropathy, cranial
nerve palsy, and/or
abnormal nerve
conduction)
Ozen et al. [4] N = 33 33 (100%) 13 (39%) 5 (15%) 1 (3%)
Kumar et al. [5] N = 9 9 (100%) 7 (78%) 0 (0%) 0 (0%)
Diaz-Perez et al. [6] N = 5 5 (100%) 3 (60%) 5 (100%) 3 (60%)
Fink [7] N = 5 5 (100%) 5 (100%) 5 (100%) 0 (0%)
Tinaztepe et al. [8] N = 4 4 (100%) 4 (100%) 4 (100%) 0 (0%)
Sheth et al. [9] N = 4 4 (100%) 4 (100%) 4 (100%) 2 (50%)
Topaloglu et al. [10] N = 4 3 (75%) 2 (50%) 3 (75%) 4 (100%)
Fathalla et al. [11] N = 4 4 (100%) 3 (75%) 0 (0%) 0 (0%)
Kirkali et al. [12] N = 3 2 (67%) 0 (0%) 1 (33%) 3 (100%)
Yonis [13] N = 3 3 (100%) 0 (0%) 3 (100%) 2 (67%)
Siberry et al. [14] N = 2 2 (100%) 2 (100%) 0 (0%) 0 (0%)
Finkel et al. [15] N = 2 2 (100%) 2 (100%) 2 (100%) 1 (50%)
Eleftheriou et al. [3] N = 2 2 (100%) 0 (0%) 1 (50%) 1 (50%)
Till et al. [16] N = 2 2 (100%) 2 (100%) 0 (0%) 0 (0%)
Single case reports
[17–53] N = 37 N = 35 (95%) N = 22 (59%) N = 18 (49%) N = 5 (14%)
TOTAL N = 119 115 (96.6) 69 (58.0) 51 (42.9) 22 (18.5%)
Table 2: Frequency of therapies used in management of childhood
cPAN (N = 112).
Medication∗ N (%) References
Corticosteroid 96 (85.7)
[4, 5, 7–
14, 16, 21, 22, 24–
35, 39–41, 43–51, 53]
DMARD (azathioprine,
cyclophosphamide,
methotrexate, and
mycophenolate mofetil)
37 (33)
[4, 5, 8, 10–
12, 15, 21, 22, 29, 30,
34, 37, 45, 47–50, 53]
Penicillin 33 (29.5) [7,9,11,13,14,16,24,
37, 41, 42, 44, 46, 47]
ASA 12 (10.7) [9, 14, 24, 29, 31–
33, 38, 42, 45]
NSAID 12 (10.7) [4, 9, 11, 16, 24, 26,
28, 31, 32, 37, 41]
IVIG 11 (9.8) [9, 11, 14, 15, 35, 36,
42, 45, 51, 53]
Biologic (inﬂiximab,
etanercept) 2 (1.8) [3]
Other (colchicine,
dapsone, oxpentifylline,
ACTH, and platonin)
12 (10.7) [8, 13, 18, 29, 53]
∗Used at anytime throughout disease management
is limited to skin, joints, and muscles in the majority
with a minority having nerve involvement. Constitutional
symptoms are common. Most children have a chronic and
relapsing benign course.
We report a severe case of cPAN in a 7.5-year-old girl.
Our patient eventually responded to rituximab after not
responding to multiple corticosteroid sparing immunosup-
pressive therapies. She remains corticosteroid dependent
after 24 months. Consistent with the published literature she
is responsive to high-dose corticosteroids, but had disease
relapse as corticosteroids were weaned. Importantly, she has
not developed visceral involvement and has not evolved to
systemic PAN.
Cutaneous and systemic PAN share the same histopatho-
logic features of necrotizing arteritis of small and medium
sized vessels. Kussmaul and Meier described the ﬁrst cases of
systemic PAN in 1866 [1]. Early reports [6, 54] conﬁrm that
cPAN is a separate entity to systemic PAN. We have limited
our deﬁnition of cPAN to disease aﬀecting the skin, muscle,
joints, and peripheral nervous system, with corresponding
biopsy conﬁrmation. Any evidence of visceral involvement,
either clinically (central nervous system, pulmonary, car-
diac, gastrointestinal, or renal), radiographically (abnormal
angiography),orbyhistology(visceralbiopsy)wereclassiﬁed
as systemic PAN. Nakamura et al. [17] proposed further
restriction of the deﬁnition of cutaneous PAN in that any
extracutaneous involvement such as peripheral neuropathy
andmyalgiasmustbelimitedtothesameareaasskinlesions.
Systemic PAN and cPAN appear to be fairly distinct entities
on a clinical continuum. There are only 5 reported cases of
cPAN evolving into systemic PAN [55, 56].Arthritis 5
On review of treatment regimens reported in the lit-
erature, most children respond to corticosteroids. Peni-
cillin should be considered in children with increased
ASO titres [5, 7, 9, 16, 56]. Recent case series report
success with low-dose methotrexate, cyclophosphamide,
intravenous immunoglobulin, and biologic therapies [3,
4, 11, 57]. Eleftheriou and colleagues report the largest
cohort of pediatric patients treated with biologic therapy.
Of the 25 patients reported, 11 had PAN and 2 had cPAN
as per our case deﬁnition of skin involvement and the
absence of visceral involvement. Both patients with cPAN
responded to anti-TNF therapy; one to inﬂiximab and one
to etanercept. Overall, 8 patients with systemic PAN received
inﬂiximab and three received etanercept. Two patients with
systemic PAN required further treatment with a second
biologic agent, one each with rituximab and adalimumab.
Five other patients (unclassiﬁed vasculitis (n = 4) and
Wegener granulomatosis (n=1)) also required treatment
with a second biologic agent (rituximab (n = 2), inﬂiximab,
etanercept and anakinra (n = 1). Of concern, infectious
complications occurred in 24% of patients. The authors
concluded that biologic therapy may be helpful in treating
primary systemic vasculitis and recommend children with
PAN who fail standard therapy or have high cumulative
cyclophosphamide dose be treated with rituximab or anti-
TNF therapy [3].
Our patient had a raised ASO initially, but she did
not receive ongoing Penicillin prophylaxis. She was ini-
tially treated with high-dose corticosteroids and cyclophos-
phamide as standard recognized therapy for severe vasculitis.
She did well on cyclophosphamide but did not tolerate
weaning from monthly to 2 monthly infusions and was
switched to inﬂiximab and methotrexate to minimize cumu-
lative cyclophosphamide dose. Consistent with the literature,
she initially responded to inﬂiximab but was switched to
rituximab with cyclophosphamide due to failure to control
disease activity despite high dose (10mg/kg) and frequent
inﬂiximab infusions (every 4 weeks). Of interest she did not
have any positive autoantibodies, and the literature suggests
eﬃcacy of rituximab is not conﬁned to antibody positive
patients [3]. Currently she is maintained on 5mg prednisone
and methotrexate. On her current therapy she is doing well
and has returned to school and regular physical activity.
There are inherent limitations of a retrospective study
of cases reported in the literature over a 60 year time
period. Many of the case series did not report individual
characteristics; therefore the data could not be extracted
on individual patients. Immunosuppressive therapies have
changed over time and biologic therapies appear promising
for children who fail standard therapies.
In summary, cPAN can be challenging to diagnose and
manage. A diagnosis of cPAN should be considered in a
child with fever, tender subcutaneous nodules, livido retic-
ularis, and arthralgias/arthritis. Most children respond to
corticosteroids and have a benign course, but some children
may be corticosteroid dependent or corticosteroid resistant,
necessitating other immunosuppressive agents including
DMARDs and biologic therapies. There is no ﬁrm choice of
ﬁrst-line biologic therapy for childhood PAN, and we report
a case of cPAN responsive to rituximab after failing TNF
inhibition. Multicentre pediatric vasculitis disease registries
are necessary to inform development and standardization of
best clinical practice for childhood cPAN.
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